Abstract:This application brief demonstrates reliable quantification of six nitrosamine impurities (NDMA, NDEA, NEIPA, NDIPA, NDBA, and NMBA) in valsartan and NDMA in ranitidine by UV detection, with the added benefit of mass confirmation by mass spectral data using an ACQUITY QDa Mass Detector. The ACQUITY Arc System with PDA Detector, integrated with an ACQUITY QDa Mass Detector for accurate mass confirmation, enables reliable quantification of nitrosamine impurities in valsartan and ranitidine drug substances. In this work, we present an HPLC method with UV detection for the simultaneous quantification of six nitrosamine impurities in valsartan drug substance, including N-nitrosodimethylamine (NDMA), N-nitroso-N-methyl-4-aminobutyric acid (NMBA), N-nitrosodiethylamine (NDEA), N-nitrosoethylisopropylamine (NEIPA), N-nitrosodiisopropylamine (NDIPA), and N-nitrosodibutylamine (NDBA). This method also enables analysis of NDMA in ranitidine drug substance. The achievable quantitation limits for nitrosamine impurities using UV detection range from 10–20 ng/mL, with method linearity over 10–1000 ng/mL producing R 2 ≥0.999. The mass spectral data from an ACQUITY QDa Mass Detector was used for quick and accurate peak identity confirmation. A single HPLC/UV method was successfully developed for the reliable quantification of six nitrosamine impurities (NDMA, NMBA, NDEA, NEIPA, NDIPA, and NDBA) in valsartan and NDMA in ranitidine drug substances, with quantitation limits ranging from 10–20 ng/mL. The analysis was performed on the ACQUITY Arc System with 2998 PDA Detector, integrated with an ACQUITY QDa Mass Detector for quick and accurate peak identity confirmation. Additionally, the XSelect HSS T3 Column, a proprietary reversed-phase column, provided retentivity and specificity for all analytes. This HPLC-UV method offers a starting point for the robust quantification of nitrosamines or similar compounds.

High‐Performance Liquid Chromatography–Tandem Mass Spectrometry Method Development and Validation for Simultaneous Determination of Seven Nitrosamine and Azidomethyl‐Biphenyl‐Tetrazole Impurities in Losartan

Development of a Sensitive Headspace Gas Chromatography–Mass Spectrometry Method for the Simultaneous Determination of Nitrosamines in Losartan Active Pharmaceutical Ingredients

HPLC/APCI -MS Determination of Telmisartan in Human Plasma

Quantification and Validation of a HPLC-UV Method for Simultaneous Analysis of Nitrosoamine Impurities (NDMA, NDEA and NDIPA) in Losartan

Highly Sensitive and Robust LC-MS/MS Method for Determination up to 15 Small Molecule Nitrosamine Impurities in Pharmaceutical Drug Substances

Reliable HPLC/UV Quantification of Nitrosamine Impurities in Valsartan and Ranitidine Drug Substances

Evaluation of a Novel LC-MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials

Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometry.

Profiling Detection and Validation of Six Sartan Substances in Human Urine by LC-MS/MS

Ultra‐high‐performance liquid chromatography‐tandem mass spectrometry analytical method for the determination of nitrosamine drug substance‐related impurity in sitagliptin base and salts

A headspace GC–MS method to quantify nitrosamine impurities and precursors in drug products: Method validation and product testing

Application of advanced high resolution mass spectrometric techniques for the analysis of losartan potassium regarding known and unknown impurities

Convenient analysis of sartan adulteration in herbal oral liquids using cotton fiber-supported liquid extraction and with high-performance liquid chromatography-fluorescence detection

Targeted and untargeted screening for impurities in losartan tablets marketed in Germany by means of liquid chromatography/high resolution mass spectrometry

Development and Validation of an HPLC-FLD Method for the Determination of NDMA and NDEA Nitrosamines in Lisinopril Using Pre-Column Denitrosation and Derivatization Procedure

An Agile and Accurate Approach for N-Nitrosamines Detection and Quantification in Medicines by DART-MS

A Practical HPLC-MS Method for the Analysis of Nitrosamine Drug Substance Related Impurities Using an Inexpensive Single Quadrupole Mass Spectrometer

DETERMINATION OF N-NITROSODIMETHYL AMINE (NDMA) AND N-NITROSODIETHYL AMINE (NDEA) IN MEDICINES CONTAINING SARTAN AND ITS DERIVATIVES

A SENSITIVE, ECONOMICAL BIOANALYTICAL LC-MS/MS METHOD FOR SIMULTANEOUS ANALYSIS OF IRBESARTAN AND HYDROCHLOROTHIAZIDE

Fast gradient high performance liquid chromatography method with UV detection for simultaneous determination of seven angiotensin converting enzyme inhibitors together with hydrochlorothiazide in pharmaceutical dosage forms and spiked human plasma and urine.

Safety and human health: The landscape of an effective UPLC-MS/MS method for the identification and quantification of N-Nitroso Hydrochlorothiazide impurity in Hydrochlorothiazide